Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Free Cash Flow (2020 - 2025)

Journey Medical (DERM) has disclosed Free Cash Flow for 6 consecutive years, with -$2.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow fell 105.96% year-over-year to -$2.4 million, compared with a TTM value of -$3.9 million through Sep 2025, up 85.89%, and an annual FY2024 reading of -$24.1 million, down 10152.92% over the prior year.
  • Free Cash Flow was -$2.4 million for Q3 2025 at Journey Medical, down from -$942000.0 in the prior quarter.
  • Across five years, Free Cash Flow topped out at $18.7 million in Q3 2023 and bottomed at -$19.1 million in Q1 2022.
  • Average Free Cash Flow over 5 years is -$2.7 million, with a median of -$3.2 million recorded in 2021.
  • The sharpest move saw Free Cash Flow tumbled 1504.56% in 2022, then skyrocketed 357.44% in 2023.
  • Year by year, Free Cash Flow stood at -$3.2 million in 2021, then dropped by 19.65% to -$3.8 million in 2022, then plummeted by 330.66% to -$16.5 million in 2023, then surged by 113.47% to $2.2 million in 2024, then plummeted by 207.1% to -$2.4 million in 2025.
  • Business Quant data shows Free Cash Flow for DERM at -$2.4 million in Q3 2025, -$942000.0 in Q2 2025, and -$2.8 million in Q1 2025.